JP2009524601A5 - - Google Patents

Download PDF

Info

Publication number
JP2009524601A5
JP2009524601A5 JP2008549598A JP2008549598A JP2009524601A5 JP 2009524601 A5 JP2009524601 A5 JP 2009524601A5 JP 2008549598 A JP2008549598 A JP 2008549598A JP 2008549598 A JP2008549598 A JP 2008549598A JP 2009524601 A5 JP2009524601 A5 JP 2009524601A5
Authority
JP
Japan
Prior art keywords
composition
candida
als protein
protein family
family member
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008549598A
Other languages
English (en)
Japanese (ja)
Other versions
JP5692963B2 (ja
JP2009524601A (ja
Filing date
Publication date
Priority claimed from US11/327,197 external-priority patent/US20070077256A1/en
Application filed filed Critical
Publication of JP2009524601A publication Critical patent/JP2009524601A/ja
Publication of JP2009524601A5 publication Critical patent/JP2009524601A5/ja
Application granted granted Critical
Publication of JP5692963B2 publication Critical patent/JP5692963B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

JP2008549598A 2006-01-06 2007-01-05 播種性カンジダ症および他の感染性因子に対するワクチン接種をするための医薬組成物および方法 Expired - Fee Related JP5692963B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/327,197 2006-01-06
US11/327,197 US20070077256A1 (en) 1999-11-19 2006-01-06 Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
PCT/US2007/000433 WO2007081896A2 (en) 2006-01-06 2007-01-05 Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012207831A Division JP5775044B2 (ja) 2006-01-06 2012-09-21 播種性カンジダ症および他の感染性因子に対するワクチン接種をするための医薬組成物および方法

Publications (3)

Publication Number Publication Date
JP2009524601A JP2009524601A (ja) 2009-07-02
JP2009524601A5 true JP2009524601A5 (enExample) 2011-02-03
JP5692963B2 JP5692963B2 (ja) 2015-04-01

Family

ID=38256965

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008549598A Expired - Fee Related JP5692963B2 (ja) 2006-01-06 2007-01-05 播種性カンジダ症および他の感染性因子に対するワクチン接種をするための医薬組成物および方法
JP2012207831A Expired - Fee Related JP5775044B2 (ja) 2006-01-06 2012-09-21 播種性カンジダ症および他の感染性因子に対するワクチン接種をするための医薬組成物および方法
JP2014105980A Withdrawn JP2014148547A (ja) 2006-01-06 2014-05-22 播種性カンジダ症および他の感染性因子に対するワクチン接種をするための医薬組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2012207831A Expired - Fee Related JP5775044B2 (ja) 2006-01-06 2012-09-21 播種性カンジダ症および他の感染性因子に対するワクチン接種をするための医薬組成物および方法
JP2014105980A Withdrawn JP2014148547A (ja) 2006-01-06 2014-05-22 播種性カンジダ症および他の感染性因子に対するワクチン接種をするための医薬組成物および方法

Country Status (10)

Country Link
US (5) US20070077256A1 (enExample)
EP (4) EP2532360B1 (enExample)
JP (3) JP5692963B2 (enExample)
AU (1) AU2007205065B2 (enExample)
CA (2) CA2636277C (enExample)
CY (1) CY1113693T1 (enExample)
DK (1) DK1982190T3 (enExample)
ES (3) ES2391580T3 (enExample)
PT (1) PT1982190E (enExample)
WO (1) WO2007081896A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8541008B2 (en) * 1999-11-19 2013-09-24 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against candidiasis
US20060083750A1 (en) * 1999-11-19 2006-04-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
US20070077256A1 (en) 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
CA2766805A1 (en) * 2009-07-03 2011-01-06 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Hyr1 as a target for active and passive immunization against candida
WO2012163533A1 (en) 2011-06-01 2012-12-06 Eth Zurich T cell epitope of candida albicans
WO2013015831A1 (en) * 2011-07-22 2013-01-31 Novadigm Therapeutics, Inc. Methods and compositions for vaccinating against staphylococcus aureus
RU2717306C2 (ru) 2013-03-15 2020-03-19 Лос-Анджелес Биомедикал Ресерч Институт Эт Харбор-Укла Медикал Центер Композиции и способы лечения грибковых и бактериальных патогенов
JP6566616B2 (ja) * 2014-08-19 2019-08-28 キヤノン株式会社 通信装置、その制御方法、およびプログラム
JP7036718B2 (ja) 2015-11-16 2022-03-15 メドインセルル 滑膜組織への医薬活性成分の小分割化及び／又は標的化の方法
JP2019507759A (ja) * 2016-03-09 2019-03-22 ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター 外陰部膣カンジダ症の予防及び治療で使用するための方法及びキット
US10308571B2 (en) * 2017-10-11 2019-06-04 Uop Llc Process for minimizing benzene, toluene, and a recycle loop in a zero benzene aromatics complex
US12324830B2 (en) 2018-04-10 2025-06-10 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Methods of treatment for Candida auris infections
EP3552620A1 (en) * 2018-04-11 2019-10-16 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Methods of treatment for candida auris infections

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1133829A (en) 1978-08-24 1982-10-19 Neil J.L. Gilmour Pasteurellosis vaccines
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5622939A (en) 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
WO1995031998A1 (en) 1994-05-23 1995-11-30 The Research & Development Institute, Inc. Candida albicans adhesin as a vaccine
US5668263A (en) 1994-12-16 1997-09-16 Smithkline Beecham Corporation Conserved yeast nucleic acid sequences
EP0831897B1 (en) 1995-06-07 2001-03-28 Pfizer Inc. In ovo vaccination against coccidiosis
CA2255669A1 (en) * 1996-05-16 1997-11-20 The Texas A & M University System Collagen binding protein compositions and methods of use
US6747137B1 (en) 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
US6703025B1 (en) * 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
US7067138B1 (en) 1999-11-19 2006-06-27 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
US8541008B2 (en) * 1999-11-19 2013-09-24 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against candidiasis
US20060083750A1 (en) * 1999-11-19 2006-04-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
US20070077256A1 (en) * 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
EP1461442B1 (en) 2001-11-30 2017-09-06 Amgen Fremont Inc. Transgenic animals bearing human ig lambda light chain genes
CA2486618C (en) 2002-05-21 2013-04-09 Schering-Plough Ltd. Methods for the in vitro culture of sporozoea sp. and uses thereof
US7241613B1 (en) 2002-06-05 2007-07-10 Oscient Pharmaceuticals Corporation Identification of Candida cell surface proteins and their uses
US7723087B2 (en) * 2002-11-12 2010-05-25 The Brigham And Women's Hospital, Inc. Nucleic acid molecules for enhanced production of a bacterial polysaccharide and methods of use thereof
KR100785601B1 (ko) 2003-11-21 2007-12-14 화이자 프로덕츠 인크. 백신 아쥬반트로서의 항생제의 용도
WO2005060713A2 (en) * 2003-12-19 2005-07-07 Inhibitex, Inc. Method of inhibiting candida-related infections using donor selected or donor stimulated immunoglobulin compositions
GB0420466D0 (en) 2004-09-14 2004-10-20 Cassone Antonio Anti-glucan antibodies
WO2006036817A2 (en) 2004-09-24 2006-04-06 Microbia, Inc. Fungal variants and uses thereof
CA2489194A1 (en) 2004-12-03 2006-06-03 Guilhem Janbon Polypeptides involved in candida biofilm formation and uses thereof
WO2007126813A2 (en) 2006-03-29 2007-11-08 Inhibitex, Inc. Cross-reactive monoclonal antibodies recognizing als family proteins
US7732187B2 (en) 2006-04-17 2010-06-08 Intervet Inc. Recombinant attenuated clostridium organisms and vaccine
EP2164511A1 (en) 2007-05-22 2010-03-24 Baylor College Of Medicine Immune complex vaccination as a strategy to enhance immunity in the elderly and other immune compromised populations
TW201010717A (en) 2008-05-29 2010-03-16 Intervet Int Bv Coccidiosis vaccines
US20100150942A1 (en) 2008-12-03 2010-06-17 Cantor Thomas L Affinity purified human polyclonal antibodies and methods of making and using them
HUE036372T2 (hu) 2009-06-22 2018-07-30 Wyeth Llc Staphylococcus aureus antigének immunogén készítményei
CA2766805A1 (en) 2009-07-03 2011-01-06 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Hyr1 as a target for active and passive immunization against candida
WO2012163533A1 (en) 2011-06-01 2012-12-06 Eth Zurich T cell epitope of candida albicans
WO2013015831A1 (en) 2011-07-22 2013-01-31 Novadigm Therapeutics, Inc. Methods and compositions for vaccinating against staphylococcus aureus
JP2014527084A (ja) 2011-09-14 2014-10-09 ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター Ｈｙｒ１由来組成物およびそれを使用する処置方法
RU2717306C2 (ru) 2013-03-15 2020-03-19 Лос-Анджелес Биомедикал Ресерч Институт Эт Харбор-Укла Медикал Центер Композиции и способы лечения грибковых и бактериальных патогенов
US20160030533A1 (en) 2013-03-15 2016-02-04 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions and methods of treating fungal and bacterial pathogens
WO2014144024A1 (en) 2013-03-15 2014-09-18 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Hyr1 compositions and methods for treating fungal and bacterial pathogens
GB201503812D0 (en) 2015-03-06 2015-04-22 Univ Aberdeen Antibody molecules and uses thereof
JP2019507759A (ja) 2016-03-09 2019-03-22 ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター 外陰部膣カンジダ症の予防及び治療で使用するための方法及びキット

Similar Documents

Publication Publication Date Title
JP2009524601A5 (enExample)
Rueda et al. Paradoxical growth of Candida albicans in the presence of caspofungin is associated with multiple cell wall rearrangements and decreased virulence
JP2010540446A5 (enExample)
CY1113693T1 (el) Φαρμακευτικες συνθεσεις και μεθοδοι για τον εμβολιασμο κατα της διαχυτης καντιντιασης και αλλων μολυσματικων παραγοντων
BRPI0819719B8 (pt) compostos de inibição de dipeptidil peptidase-iv, métodos de preparação dos mesmos, e preparações farmacêuticas contendo os mesmos como agente ativo
JP2010532765A5 (enExample)
WO2010150233A3 (en) Multimeric polypeptides of hla-g including at least two alpha3 domains and pharmaceutical uses thereof
WO2008045238A3 (en) Stabilized therapeutic small helical antiviral peptides
EP2399575A3 (en) Methods, uses and compositions for treatment of an infection by a virus of the family of flaviviridae through the farnesoid X receptor (FXR) inhibition
WO2012077950A3 (ko) 히알루론산-단백질 컨쥬게이트 및 이의 제조 방법
WO2008005084A3 (en) Methods to prevent and treat diseases
JP2018500390A5 (enExample)
WO2009131548A8 (en) Multimeric forms of antimicrobial peptides
EP3210611A3 (en) Methods of treating vascular inflammatory disorders
WO2012050896A3 (en) Protease selective supramolecular assemblies
ECSP066916A (es) Vacuna contra estreptococo agalactiae
JP2008540453A5 (enExample)
WO2005094554A3 (en) Therapeutic agents, methods, and treatments
WO2007018463A3 (en) Interaction of moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system
Kabeerdass et al. Green synthesis–mediated nanoparticles and their curative character against post COVID-19 skin diseases
WO2009005798A8 (en) Antifungal formulation and method of preparation
WO2010149283A3 (de) Phenyloxy(thio)phenylamidbenzoxa(thia)zole
JP2009507474A5 (enExample)
WO2006121895A3 (en) Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
WO2011003665A3 (en) Method of treating hair